The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to ...

The U.S. Food and Drug Administration has approved Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist, for ...

A research team from the University of Pittsburgh in the U.S. has unveiled a "living eye drop" that genetically modifies eye ...

IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m. EDT on ...

Researchers plan to begin the first patient trial in 2027 thanks to promising preclinical results from a gene therapy ...

When cutlery, insulation, packaging and other items made of polystyrene plastic break down, they can form nanoplastics up to ...

Lutikizumab improves clinical responses and pain outcomes in patients with hidradenitis suppurativa after anti-TNF failure in ...

This is the first IL-23 receptor-targeted oral peptide pill, and it is also being evaluated as a treatment for psoriatic ...

Researchers at The University of Manchester have found that tracking changes in a protein linked to inflammation (interleukin ...

Interleukin (IL)-1 is a prototypic proinflammatory cytokine. It is produced by numerous cell types (i.e., macrophages, synoviocytes, endothelial cells, chondrocytes, osteoclasts) and is found in ...

• Overall, we did not find sufficient evidence to show that medicines that block interleukin-1 (a protein involved in immune responses) are effective treatments for people with COVID-19, or whether ...

Please provide your email address to receive an email when new articles are posted on . Ebglyss is a targeted interleukin-13 inhibitor approved for the treatment of moderate-to-severe atopic ...